Low-risk prostate cancer is diagnosed in nearly half of men undergoing screening. About a third of these men harbour high-grade cancer that is not detected by conventional systematic biopsy. Should we treat men with low-risk prostate on the basis that it might be of higher grade than it seems? Should we treat it to prevent future progression to a more aggressive form of cancer? What are the nonivasive treatment options for these men? In this Review, Mark Emberton and Laurence Klotz discuss the two current choices to manage low-risk prostate cancer: active surveillance and focal therapy.
- Laurence Klotz
- Mark Emberton
